MIR210HG, which acts as an oncogene in multiple tumors, was shown to promote cervical cancer progression through the MIR210HG–miR-503-5p–TRAF4 axis, participate in methylation of the CACNA2D2 promoter region to accelerate tumorigenesis of non-small cell lung cancer, and increase glycolysis-dependent oncogenic activity by potentiating the metabolic transcription factor hypoxia-inducible factor 1α in triple-negative breast cancer [45–47]. The gene discussed is MIR210HG; the disease is cervical cancer.